<DOC>
	<DOCNO>NCT02651987</DOCNO>
	<brief_summary>This study aim explore efficacy safety lanreotide Autogel® 120 mg administer every 14 day subject grade 1 2 , metastatic locally advanced , unresectable pancreatic intestinal neuroendocrine tumour ( NETs ) progress standard dose lanreotide Autogel® 120 mg every 28 day .</brief_summary>
	<brief_title>Efficacy Safety Study Pancreatic Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histopathologically confirm , grade 1 2 , metastatic locally advanced , unresectable pNET ( pNET cohort ) midgut NET ( midgut cohort ) without hormone relate syndrome , proliferation index ( Ki67 ) ≤20 % . Positive somatostatin receptor type 2 Progression assess independent central reviewer accord RECIST v1.0 receive first line treatment lanreotide Autogel® standard dose 120 mg every 28 day least 24 week Grade 3 rapidly progressive ( within 12 week ) NET Any NET pancreatic midgut Previous treatment antitumour agent NET lanreotide Autogel® 120 mg every 28 day Gallbladder lithiasis Screening echography history cholelithiasis cholecystectomy since .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>